KANTAR HEALTH BLOG

After anxiously awaiting readout from 3 pivotal trials of immunotherapy in NSCLC, we can finally take a breath to process what we learned at AACR 2018: KEYNOTE-189, IMpower 150, and CheckMate 227 all presented positive results yesterday. While the individual and cross-trial interpretations of these studies is complex, the near-term impact on the treatment of NSCLC appears rather simple.

If you're anything like me, you dread the question from Senior Management, “What's the ROI of this multichannel marketing campaign?”. Regardless of when or how the ROI question comes, it will eventually arise and you should be prepared to answer it well.

Co-authored by Linda Zhao

Co-authored by Stephanie Amato, Ph.D.

Co-authored by Len Kusdra, Ph.D.